Key clinical point: An orally dissolving tablet formulation of rimegepant is safe and effective.
Major finding: About 20% of patients who received rimegepant were pain-free at 2 hours, compared with 12% of controls.
Study details: A randomized, double-blind, phase 3 trial of 1,186 patients with migraine.
Disclosures: The study was supported by Biohaven, which is developing rimegepant. Several of the investigators are employees of Biohaven.
Lipton RB et al. N Eng J Med. 2019 Jul 11; 381:142-9.